- Home
- CHRS vs HLVX Comparison
CHRS vs HLVX Comparison
Compare CHRS & HLVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHRS
- HLVX
- Stock Information
- Founded
- CHRS 2010
- HLVX 2020
- Country
- CHRS United States
- HLVX United States
- Employees
- CHRS N/A
- HLVX N/A
- Industry
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- HLVX Biotechnology: Pharmaceutical Preparations
- Sector
- CHRS Health Care
- HLVX Health Care
- Exchange
- CHRS Nasdaq
- HLVX Nasdaq
- Market Cap
- CHRS 100.9M
- HLVX 87.6M
- IPO Year
- CHRS 2014
- HLVX 2022
- Fundamental
- Price
- CHRS $1.10
- HLVX $1.79
- Analyst Decision
- CHRS Strong Buy
- HLVX Hold
- Analyst Count
- CHRS 4
- HLVX 5
- Target Price
- CHRS $6.13
- HLVX $2.33
- AVG Volume (30 Days)
- CHRS 3.1M
- HLVX 130.3K
- Earning Date
- CHRS 11-06-2024
- HLVX 11-07-2024
- Dividend Yield
- CHRS N/A
- HLVX N/A
- EPS Growth
- CHRS N/A
- HLVX N/A
- EPS
- CHRS N/A
- HLVX N/A
- Revenue
- CHRS $304,340,000.00
- HLVX N/A
- Revenue This Year
- CHRS $3.33
- HLVX N/A
- Revenue Next Year
- CHRS $16.77
- HLVX N/A
- P/E Ratio
- CHRS N/A
- HLVX N/A
- Revenue Growth
- CHRS 44.19
- HLVX N/A
- 52 Week Low
- CHRS $0.66
- HLVX $1.55
- 52 Week High
- CHRS $3.70
- HLVX $20.22
- Technical
- Relative Strength Index (RSI)
- CHRS 69.14
- HLVX 41.10
- Support Level
- CHRS $0.70
- HLVX $1.80
- Resistance Level
- CHRS $0.89
- HLVX $2.02
- Average True Range (ATR)
- CHRS 0.10
- HLVX 0.07
- MACD
- CHRS 0.04
- HLVX -0.01
- Stochastic Oscillator
- CHRS 93.70
- HLVX 0.00
About CHRS Coherus BioSciences Inc.
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.
About HLVX HilleVax Inc.
HilleVax Inc is a clinical-stage biopharmaceutical company. The company is focused on developing and commercializing novel vaccines. The firm's initial program, HIL-214, is a virus-like particle (VLP) based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection.